The content of this page has no intent to diagnose, recommend treatment or cure for any disease. When considering use of CBD for any condition please consult with your physician.
"If the misery of the poor be caused not by the laws of nature , but by our institutions, great is our sin." -Charles Darwin
Science is hope, knowledge is hope, be your own hope.
What is CBD. CBD is the medical portion of medical marijuana. Medical marijuana, from the marijuana plant, is a molecule composed of THC-CBD. The hemp plant contains a very very small amount of THC and is largely composed of CBD (H-CBD). Though THC has some important health benefits. The main portion of the benefits received from the THC-CBD molecule is the CBD portion. The ratio of CBD:THC for marijuana ranges from 1:1 to 18:1. H-CBD is non hallucinogenic and is a cousin to the marijuana plant. It is the CBD that comes from the hemp plant that we at GM Silver Solutions study.
Cannabidiol (CBD) has been used medicinally for over a thousand years but has been banned in the US since the 1940's. Medical professionals are seeking new ways to improve patient health through natural methods. I am one of them. I am not a traditional western medicine denier; western medicine has a profound place in the world of health care. Unfortunately, research has shown the truth to a long-held suspicion of greed and power that overwhelms the decency of pure thought and purpose concerning the real needs of those suffering from life-threatening and debilitating illnesses. A movement toward the use of CBD has been slowly developing over the last couple of decades. This momentum is accelerating and is about to change the way healthcare professionals look at treating those suffering from some of the most common, deadly and debilitating conditions by using CBD.
We will only promote the things we are highly confident about. Our confidence comes from reviewing the science which is found in articles such as those below. We receive regular feedback about people being spared of their afflictions with the use of CBD. We await your testimonial as well.
There is an overwhelming amount of research on the wide range uses of CBD, it is commonly used to reduce ANXIETY, help those with SLEEP DISORDERS, REDUCE INFLAMMATION, treat ACHY JOINTS AND MUSCLES, help those with SEIZURES and is a very effective ANTI-OXIDANT.
Below you will find a small number of search articles, there are many more, on the effectiveness of CBD for the conditions listed above. This list will continue to grow and we at GM Silver Solutions will continue to perform due diligence in our commitment to studying and disseminating valued information on the benefits of CBD. This has been an exciting journey for us and we hope for you as well. We do all we can to make ourselves available to you. If you have any questions regarding the following references and or use of CBD please do not hesitate to call, 1-800-447-8803
"The world of knowledge is at our fingertips. Knowledge is power and the knowledge of CBD is vastly abundant. Do your own homework"
Dr. Richard K Madsen
(The following information is not intended to diagnose, treat, cure or prevent any disease or condition. This information is intended to help you on your path to discovering health and happiness through natural means).
The following are "abstracts" from several studies showing the benefits to alleviating some of the conditions mentioned above. The "abstracts" are followed by the information of the article from which it is copied. For those wanting a more in depth understanding for themselves; simply "click", "copy" and "paste" the "TITLE" to your search bar.
The "Abstract" of the next two articles are probably of the most important to understanding the benefits of CBD.
Anti-Inflammation/Achy muscles and joints
The mediators and cellular effectors of inflammation are important constituents of the local environment of tumours. In some types of cancer, inflammatory conditions are present before a malignant (very bad) change occurs. Conversely, in other types of cancer, an oncogenic (cancer producing) change induces an inflammatory microenvironment that promotes the development of tumours. Regardless of its origin, 'smouldering' inflammation in the tumour microenvironment has many tumour-promoting effects. It aids in the proliferation and survival of malignant cells, promotes angiogenesis (blood vessel formation) and metastasis (the spread of cancer cells throughout the body), subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents. The molecular pathways of this cancer-related inflammation are now being unraveled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
TITLE: Cancer-related inflammation; Published: 01 July 2008, Alberto Mantovani, Paola Allavena, Antonio Sica & Frances Balkwill; Nature volume 454, pages436–444(2008)Cite this article.
"Pain and inflammation are the body’s physiological responses to tissue injury, infection and genetic changes . These responses can be divided into two phases: acute (short term)and chronic (long term, greater than three months). The acute phase is the early, non-specific phase and is characterized by local vasodilatation, increased capillary permeability, the accumulation of fluid and blood proteins in the interstitial spaces (swelling), the migration of neutrophils (white blood cells) out of the capillaries, and the release of inflammatory mediators (e.g., cytokines, lymphokines and histamine). Pain is produced by all these pro-inflammatory agents, that also lead to hyperalgesia (excessive pain) through the activation of the corresponding receptors, which are expressed by nociceptive terminals (pain receptors). If the condition that causes the damage is not resolved, the inflammatory process progresses towards subacute/chronic inflammation, which is characterized by immunopathological changes (white blood cells attacking the host, ie; auto-immune disorders), such as the infiltration of inflammatory cells, the overexpression of pro-inflammatory genes, the dysregulation of cellular signalling and the loss of barrier function. Chronic state of inflammation plays an important role in the onset of classic inflammatory diseases (e.g., arthritis) but also of various diseases, including cardiovascular and neurodegenerative diseases, diabetes, cancer, asthma. The suppression or inhibition of inflammatory/pro-inflammatory mediators using synthetic anti-inflammatory compounds (both steroidal and non-steroidal) is one of the major routes for the treatment of inflammatory disorders. However, several common side effects, including gastric irritation and ulceration, renal (kidney) and hepatic (liver) failure, haemolytic anaemia (anemia due to premature break down of red blood cells), asthma exacerbation, skin rashes, are often associated with the use of synthetic anti-inflammatory drugs. Increasing amounts of evidence demonstrate that the endocannabinoid system actively participates in the pathophysiology of osteoarthritis-associated joint pain. Production and release of endocannabinoids are mediated, during inflammatory-joint disease, by the generation of pro inflammatory cytokines (interferon [IFN]-c, interleukin (IL-12, IL-15, IL-17, IL-18), chemokines, chemical mediators, such as nitric oxide synthetase (NOS)-2, cyclooxygenase-2 (COX-2), matrix metalloproteinases (MMPs) and various other arachidonic acid metabolic by-products. Overall, preclinical and clinical data support the potentially effective anti-inflammatory properties of endocannabinoid agonists that target CB2 receptors.
TITLE: Cannabinoid Delivery Systems for Pain and Inflammation Treatment; Molecules. 2018; 23(10): 2478. Published online 2018 Sep 27. doi: 10.3390/molecules23102478 , Natascia Bruni,1 Carlo Della Pepa,2 Simonetta Oliaro-Bosso,2 Enrica Pessione,3 Daniela Gastaldi,4 and Franco Dosio2,
Side note: One of the benefits of CBD, specifically Abn-CBD, is to activate potassium hyperpolarization and to release NO (nitric oxide). These actions are very beneficial for vaso-relaxation of arteries and to reduce platelet aggregation (blood clotting). Things to include in your diet to aid in the same process is L-citrulline, citrulline malate, spinach, beet roots and flavonoids. Exercise will also produce NO production.
Aute lung injury is an inflammatory condition for which treatment is mainly supportive because effective therapies have not been developed. Cannabidiol, a non-psychotropic cannabinoid component of marijuana (Cannabis sativa), has potent immunosuppressive and anti-inflammatory properties. Therefore, we investigated the possible anti-inflammatory effect of cannabidiol in a murine model of acute lung injury. Analysis of total inflammatory cells and differential in bronchoalveolar lavage fluid was used to characterize leukocyte migration into the lungs; myeloperoxidase activity of lung tissue and albumin concentration in the bronchoalveolar lavage fluid were analyzed by colorimetric assays; cytokine/chemokine production in the bronchoalveolar lavage fluid was also analyzed by Cytometric Bead Arrays and Enzyme-Linked Immunosorbent Assay (ELISA). A single dose of cannabidiol (20 mg/kg) administered prior to the induction of LPS (lipopolysaccharide)-induced acute lung injury decreases leukocyte (specifically neutrophil) migration into the lungs, albumin concentration in the bronchoalveolar lavage fluid, myeloperoxidase activity in the lung tissue, and production of pro-inflammatory cytokines (TNF and IL-6) and chemokines (MCP-1 and MIP-2) 1, 2, and 4 days after the induction of LPS-induced acute lung injury. Additionally, adenosine A2Areceptor is involved in the anti-inflammatory effects of cannabidiol on LPS-induced acute lung injury because ZM241385 (4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol) (a highly selective antagonist of adenosine A2A receptor) abrogated all of the anti-inflammatory effects of cannabidiol previously described.
Thus, we show that cannabidiol has anti-inflammatory effects in a murine model of acute lung injury and that this effect is most likely associated with an increase in the extracellular adenosine offer and signaling through adenosine A2A receptor.
TITLE: CBD and its affects on inflamed lung tissue. Immunopharmacology and inflammation Cannabidiol a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2A receptor, Ribeiro 1, Viviane Ferraz-de-Paula, Milena L Pinheiro, Luana B Vitoretti, Domenica P Mariano-Souza, Wanderley M Quinteiro-Filho, Adriana T Akamine, Vinícius I Almeida, João Quevedo, Felipe Dal-Pizzol, Jaime E Hallak, Antônio W Zuardi, José A Crippa, João Palermo-Neto, PMID: 22265864, DOI: 10.1016/j.ejphar.2011.12.043
"CBD was shown to have anxiolytic, antipsychotic and neuroprotective properties. In addition, basic and clinical investigations on the effects of CBD have been carried out in the context of many other health conditions, including its potential use in epilepsy, substance abuse and dependence, schizophrenia, social phobia, post-traumatic stress, depression, bipolar disorder, sleep disorders, and Parkinson."
TITLE: Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age, José A Crippa 1 2, Francisco S Guimarães 2 3, Alline C Campos 2 3, Antonio W Zuardi 1 2
"A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded..."
"Many different cultures have used the Cannabis plant to treat a plethora of ailments. Practitioners in ancient China targeted malaria, menstrual symptoms, gout, and constipation. During medieval times, cannabis was used for pain, epilepsy, nausea, and vomiting, and in Western medicine it was commonly used as an analgesic. In the US, physicians prescribed Cannabis sativa for a multitude of illnesses until restrictions were put in place in the 1930s and then finally stopped using it in 1970 when the federal government listed marijuana as a Schedule I substance, claiming it an illegal substance with no medical value. California was the first state to go against the federal ban and legalize medical marijuana in 1996. As of June 2018, 9 states and Washington, DC, have legalized recreational marijuana, and 30 states and Washington, DC, allow for use of medical marijuana."
"...Anxiety scores decreased fairly rapidly, and this decrease was sustained during the study period.
TITLE: Cannabidiol in Anxiety and Sleep: A Large Case Series ,Scott Shannon 1, Nicole Lewis 2, Heather Lee 3, Shannon Hughes 4, Perm J. 2019; 23: 18-041. Published online 2019 Jan 7. doi: 10.7812/TPP/18-041 PMCID: PMC6326553, PMID: 30624194
In summary, AA-5-HT (a sleep promoting hormone) promotes sleep and decreases waking-related neurotransmitters in the lights-off period and modulates sleep homeostasis in the presence of wake-promoting compounds such as CBD... . The full understanding of the mechanisms through which AA-5-HT modulates sleep awaits fruther investigation.
TITLE: Role of N-Arachidonoyl-Seotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation, Front Mol Neurosci. 2017;10:152. Published online 2017 May 30. doi:10.3389/fnmol.2017.00152. Eric Murillo Rodríguez,1,2,3,4,* Vincenzo Di Marzo,4,5 Sergio Machado,4,6,7 Nuno B. Rocha,4,8 André B. Veras,4,9,10 Geraldo A. M. Neto,4,6 Henning Budde,4,11,12,13 Oscar Arias-Carrión,4,14 and Gloria Arankowsky-Sandoval4,15
"...four pivotal double-blind, placebo-controlled, randomized clinical trials (RCTs) on overall 154 DS (Dravet Syndrome) patients and 396 LGS (Lennox-Gestaut Syndrome) ones, receiving CBD 10 or 20 mg/kg/day BID (150lbs. is 68kg, therefore the dosage for a 150lb person would be 680mg to 1360mg per day) as active treatment. The primary endpoint (reduction in monthly seizure frequency) was met by both CBD doses.
TITLE: Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects; Alessandra Morano,1 Martina Fanella,1 Mariarita Albini,1 Pierangelo Cifelli,2,3 Eleonora Palma,2 Anna Teresa Giallonardo,1 and Carlo Di Bonaventura1 Neuropsychiatr Dis Treat. 2020; 16: 381–396. Published online 2020 Feb 7. doi: 10.2147/NDT.S203782
And then there are the more spectacular benefits of long term use of CBD. The following topic, Cardiovascular, is my favorite area for the study of CBD.
Cannabidiol (CBD) has beneficial effects in disorders as wide ranging as diabetes, Huntington's disease, cancer and colitis. Accumulating evidence now also suggests that CBD is beneficial in the cardiovascular system. CBD has direct actions on isolated arteries, causing both acute and time-dependent vasorelaxation. In vitro incubation with CBD enhances the vasorelaxant responses in animal models of impaired endothelium-dependent vasorelaxation. CBD protects against the vascular damage caused by a high glucose environment, inflammation or the induction of type 2 diabetes in animal models and reduces the vascular hyperpermeability associated with such environments. A common theme throughout these studies is the anti-inflammatory and anti-oxidant effect of CBD. In the heart, in vivo CBD treatment protects against ischaemia-reperfusion damage and against cardiomyopathy associated with diabetes. Similarly, in a different model of ischaemia-reperfusion, CBD has been shown to reduce infarct size and increase blood flow in animal models of stroke, sensitive to 5HT(1A) receptor antagonism. Although acute or chronic CBD treatment seems to have little effect on haemodynamics, CBD reduces the cardiovascular response to models of stress, applied either systemically or intracranially, inhibited by a 5HT(1A) receptor antagonist. In blood, CBD influences the survival and death of white blood cells, white blood cell migration and platelet aggregation. Taken together, these preclinical data appear to support a positive role for CBD treatment in the heart, and in peripheral and cerebral vasculature.
TITLE: Is the cardiovascular system a therapeutic target for cannabidiol? Christopher Stanley et al. Br. J. Clin. Pharmacol. 2013 Feb; 75(2): 313-322.
"This study demonstrates that CBD is cardioprotective in the acute phase of I/R (ischemic reperfusion) by both reducing ventricular arrhythmias and attenuating infarct size. The anti-arrhythmic effect, but not the tissue sparing effect, may be mediated through an inhibitory effect on platelet activation. "
TITLE: Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol, . 2010 Jul;160(5):1234-42. doi: 10.1111/j.1476-5381.2010.00755.x. Sarah K Walsh 1, Claire Y Hepburn, Kathleen A Kane, Cherry L Wainwright; PMID: 20590615, PMCID: PMC2936031, DOI: 10.1111/j.1476-5381.2010.00755
"In conclusion, we have shown that CBD causes reduced infarct size in an in vivo rat model of ischemia and reperfusion. Furthermore, it seems that this effect is not direct and may be mediated by a reduced inflammatory response. Thus CBD may be a promising novel treatment for myocardial ischemia."
TITLE: Cannabidiol, a non-psychoactive constituent, protects against myocardial ischemic reperfusion injury; Ronen Durst, Haim Danenberg, Ruth Gallily, Raphael Mechoulam, Keren Meir, 01 DEC2007; https://doi.org/10.1152/ajphea...
Irritable Bowel Syndrome (IBS):
"...the fact that compounds such as PEA (palmitoylethanolamide), CBD and peppermint oil display a very large safety profile and have been proving beneficial to improve IBS symptoms..."
TITLE: Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment Viola Brugnatelli 1, Fabio Turco 2, Ulderico Freo 3, Gastone Zanette 1
"Our results therefore indicate that CBD indeed unravels a new therapeutic strategy to treat inflammatory bowel diseases."
TITLE: Irritable Bowl Syndrome: Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis Daniele de Fillippis et al. https://koi.org/10.1371/journa...
TITLE: Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy. Mariana Babayeva et al. Parkinson’s Disease, 2016 Dec 5,
TITLE: GPR55: A therapeutic target for Parkinson’s disease? Celorrio M et al. Neuropharmacology, 2017 Oct;125:319-332.
TITLE: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. D. R. Blake et al. Rheumatology, Vol 45, Iss 1,1 Jan 2006, 50-52,
Autoimmune Liver Disease:
TITLE: Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells. Venkatesh L. Hegde et al, Mol Pharmacol, 74:20-33, 2008
TITLE: Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes. Attila Olah et al. The J Clin Invest. 2014;124(9):3713-3724.
TITLE: Evaluation of Serum Cytokines Levels and the Role for Cannabidiol Treatment in Animal Model of Asthma. Francieli Vuolo et al. Mediators of Inflammation, Article ID 538670, 5 pages
TITLE: Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: roe for the adenosine A(2A) receptor. Ribeiro A et al, Eur J Pharmacol. 2012 Mar 5;678(1-3):78-75
TITLE: Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Yasmin L. Hurd et al, Neurotherapeutics. 2015 Oct; 12(4): 807-805
"...increasing evidence exist that plant, synthetic, and endogenous cannabinoids (endocannabinoids) are able to exert a growth inhibitory action on various cancer cell types."
TITLE: Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma Alessia Ligresti et al. JPET 318:1378-1387,2006
TITLE: p38MAPK is involved in CB2 receptor-induced apoptosis of human leukemia cells. Blanca Herrera et al. FEBS Lett 579, 2005 Sept 12;579(22):5084-8.